GF Fund Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

GF Fund Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$233K	Sell	4,071 -244	-6%	-$13.4K	﹤0.01%	258
2026 Q1	$244K	Buy	4,315 +541	+14%	+$31.5K	﹤0.01%	268
2025 Q4	$224K	Sell	3,774 -357	-9%	-$19.4K	﹤0.01%	285
2025 Q3	$224K	Sell	4,131 -749	-15%	-$42.8K	﹤0.01%	277
2025 Q2	$268K	Hold	4,880	–	–	0.01%	296
2025 Q1	$345K	Buy	4,880 +878	+22%	+$59.1K	0.01%	285
2024 Q4	$263K	Buy	+4,002	New	+$268K	0.01%	265

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

GF Fund Management's BMRN Position: Q2 2026 in Review

GF Fund Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 5.7% in Q2 2026, selling an estimated $13.4K and leaving 4,071 shares worth $233K. The position accounts for ﹤0.01% of the portfolio, ranked #258.

GF Fund Management first reported a position in BMRN in Q4 2024 and has held it in 7 quarters since. The position peaked at $345K in Q1 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

GF Fund Management held 4,071 shares of BioMarin Pharmaceuticals worth $233K as of Q2 2026.
GF Fund Management sold 244 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $13.4K.
BioMarin Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #258 holding.
GF Fund Management first reported a position in BioMarin Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
GF Fund Management's BioMarin Pharmaceuticals position peaked at $345K in Q1 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.